Organon & Co. Stock News

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon divests the JADA System for up to $465 Million to Laborie.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon to announce Q3 2025 financial results on November 10, 2025.

Organon & Co. shares plunged Monday, October 27th, after CEO Kevin Ali resigned amid an audit committee investigation into wholesaler sales irregularities. Despite the scandal, OGN's valuation at $7 per share is extremely cheap compared to peers, with a diversified product portfolio and global reach. The main risk is OGN's heavy $8.3 billion net debt load, which could hinder share price recover...

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- On October 27, 2025, investors in Organon & Co. (NYSE: OGN) saw the price of their shares plummet $2.10 (-23%) after the company announced the findings of its Audit Committee's investigation into improper wholesale sales practices for Nexplanon and CEO Kevin Ali's resignation.

Organon said on Monday CEO Kevin Ali will resign from his role and be replaced by Joseph Morrissey on an interim basis, after an internal investigation into wholesaler sales practices for its Nexplanon contraceptive implant.

JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN) (“Organon” or “the company”) today announced that its Board of Directors has appointed the Company's Executive Vice President and Head of Manufacturing & Supply, Joseph Morrissey, Interim Chief Executive Officer. Board Chair Carrie S. Cox will also take on additional responsibilities on an interim basis as Executive Chair to support Mr. Mo...

Organon remains a buy as the stock trades at distressed valuations despite stable fundamentals and progress on debt reduction. OGN's Women's Health and Biosimilars segments drive growth, offsetting revenue declines from loss of exclusivity in established brands like Atozet. Management's focus on operational efficiency and aggressive deleveraging, aided by a dividend cut, positions OGN for a pot...

SHANGHAI & JERSEY CITY, N.J.--(BUSINESS WIRE)--European Commission Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars.